

**AMENDMENTS TO THE CLAIMS**

Claims 1-31 have been canceled.

32. (New) Pharmaceutical compositions of the peptides, secreted by the snake venom glands particularly *Bothrops Jararaca*, vasopeptidases inhibitors, Evasins, their analogues and derivatives characterized for comprising:

**a) oligopeptides of 5-13 amino acids**

EVASIN-5, SEQ ID No.1 to SEQ ID No. 103,

EVASIN-6, SEQ ID No. 104 to SEQ ID No. 243,

EVASIN-7, SEQ ID No. 244 to SEQ ID No.325,

EVASIN-9, SEQ ID No.326 to SEQ ID No.422 and SEQ ID No.595,

EVASIN-10, SEQ ID No.423 to SEQ ID No. 516,

EVASIN-11, SEQ ID No. 517 to SEQ ID No. 556,

EVASIN-12, SEQ ID No.557 to SEQ ID No.589,

EVASIN-13, SEQ ID No.590 to SEQ ID No.594;

b) inclusion compounds of the Evasins, their analogues or derivatives in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients acceptable pharmaceutically, alone or mixed or associated at least with another active pharmacological agent;

c) the Evasins, SEQ ID No. 1 to SEQ ID No. 595, their analogues and derivatives included or not in cyclodextrins microencapsulated or not in controlled-release systems such as liposomes and biodegradable polymers and/or mixtures.

33. (New) Pharmaceutical compounds of the Evasins, their analogues and derivatives characterized by utilizing the Evasins 7a, SEQ ID No.253, EVASIN-10c, SEQ ID No.472, 11e, SEQ ID No. 555, 12b, SEQ ID No. 557, their analogues and derivatives as a molecular model for development of drugs and/or formulations based on peptides compounds and/or non-peptide vasopeptidase inhibitors.

34. (New) Pharmaceutical compositions of the Evasins, SEQ ID No. 1 to SEQ ID No. 595, their analogues and derivatives characterized by utilizing the Evasins 7a, SEQ ID No.253, EVASIN-10c, SEQ ID No.472, 11e, SEQ ID No. 555, 12b, SEQ ID No. 557, their analogues and derivatives as a molecular model for development of drugs and/ or formulations based in peptides compound and/or non-peptide ligand agonists and antagonists of the angiotensin converting enzyme bound to the membrane.

35. (New) Compositions of the Evasins, their analogues and derivatives, except the Evasins 7a, SEQ ID No.253, according to claim 32 characterized for presenting differential inhibitory activity for the neutral endopeptidase ( $K_i$  in the micro molar range) and the angiotensin I converting enzyme ( $K_i$  in the nano molar range).

36. (New) Pharmaceutical compositions of the Evasins, their analogues and derivatives according to claim 32 characterized for presenting selective inhibitory activity for the C-

terminal domain of the angiotensin I converting enzyme, being 50 a 400 fold more potent for the C – domain than for the N-domain.

37. (New) Pharmaceutical compositions of the Evasins, their analogues and derivatives according to claim 32 characterized for presenting selective binding to the C-terminal domain of the angiotensin I converting enzyme, being 50 a 400 fold more potent to the C domain than for the N-domain.

38. (New) Pharmaceutical compositions to the Evasin-7a, SEQ ID No.253, their analogues and derivatives according to claim 32 characterized for presenting similar inhibitory activity similar to the neutral endopeptidase and the angiotensin I converting enzyme.

39. (New) Utilization of the Evasins 7a, SEQ ID No.253, EVASIN-10c, SEQ ID No.472, 11e, SEQ ID No. 555, 12b, SEQ ID No. 557, their analogues and derivatives as a molecular model to the development of drugs and / or formulations based on peptide compounds and/or non-peptide compounds characterized for presenting vasodilator and/or vasoprotector activity.

40. (New) Pharmaceutical compositions of the Evasins, their analogues and derivatives according to claim 32 for application in the study and treatment of arterial hypertension and others cardiovascular diseases and their complications characterized by the use of inclusion

compounds or association of the Evasins, their analogues and derivatives with the cyclodextrin and their derivatives, microencapsulated or not in controlled-release system such as example, liposome and the biodegradable polymers, and/or mixtures.

41. (New) Pharmaceutical compositions of the Evasins, their analogues and derivatives according to claim 32 useful for the study and treatment of acute myocardial infarction, left ventricular hypertrophy diabetic, vasculopathy, peripheral ischemia, angina, progressive heart failure after a myocardial infarction, atherosclerosis, tumors, diabetes melitus, sperm motility, blockade of spermatogenesis, nephropathies, sexual dysfunction, gastrointestinal and gynecologic disorders, angiogenesis, hair loss, blood diseases, angioplasty (restenosis after-angioplasty, endoluminal protese) in warm-blood animals characterized by the use of inclusion compounds or association of the Evasins, their analogues and derivatives with cyclodextrins and their derivatives, microencapsulated or not in controlled-release systems such as the liposome and the biodegradable polymers and/or mixtures.

42. (New) Pharmaceutical compositions according to claim 32 characterized by the mixture of the organic-aqueous solids or solutions of cyclodextrins or derivatives of cyclodextrins selected from the group containing alkyl, hydroxyalkyl, hydroxyalkyl, hydroxypropyl and acyl or cyclodextrins with cross-bonds or cyclodextrins polymers with solutions of Evasins, their analogues and derivatives at a molar ratio of 1:1 or 1:2.

43. (New) Pharmaceutical compositions of the SEQ ID No. 1 to SEQ ID No. 595, their analogues and derivatives characterized by the use of the cyclodextrins, or others controlled-release systems including, liposomes, biodegradable polymers derivatives of biodegradable polymers or mixture of these systems.

44. (New) Utilization of the Evasins SEQ ID No. 1 to SEQ ID No. 595, their analogues and derivatives as molecular models for the development of drugs and/or formulations with differential inhibitory activity for the neutral endopeptidase and the angiotensin I converting enzyme according to the claim 35, characterized for presenting a lower inhibitory activity for the neutral endopeptidase and consequently with a smaller possibility of incidence of collateral effects such as cough and angiodema.

45. (New) Pharmaceutical compositions for the study and treatment of arterial hypertension and others cardiovascular diseases and their complications characterized by the mixture of organic-aqueous or solid solutions of cyclodextrins or derivatives of cyclodextrin selected from the groups containing alquil, hydroxialquil, hydroxipropil and acyl or cyclodextrins with crossed bonds or polymers of cyclodextrins, with aqueous or solids solutions of Evasins SEQ ID No. 1 to SEQ ID No. 595, their analogues and derivatives.

46. (New) Pharmaceutical compositions to study and treatment of the acute myocardial infarction, left ventricular hypertrophy diabetic vasculopathy, peripheral ischemia, angina,

progressive heart failure after a myocardial infarction, atherosclerosis, tumors, diabetes melitus, sperm motility, blockade of spermatogenesis, nephropathies, sexual dysfunction, gastrointestinal and gynecologic disorders, angiogenesis, hair loss, blood diseases, angioplasty (restenosis after-angioplasty, endoluminal protese) in warm-blood animals characterized by mixture of organic-aqueous or solid solutions of cyclodextrins or derivatives of cyclodextrins selected from the group containing alkyl, hydroxyalkyl, hydroxypropyl and acyl or cyclodextrins with crossed bonds or polymers of cyclodextrins at a molar ratio of 1:1 or 1:2 with aqueous or solid solutions of Evasins SEQ ID No. 1 to SEQ ID No. 595, their analogues and derivatives.

47. Pharmaceutical compositions to be used as male contraceptive characterized by the mixture of organic-aqueous or solid solutions of cyclodextrins or derivatives of cyclodextrins selected from the group containing alkyl, hydroxyalkil, hydroxypropyl and acyl or cyclodextrins with crossed bonds or polymers cyclodextrins at a molar ratio of 1:1 or 1:2 with aqueous or solid solutions of Evasins SEQ ID No. 1 to SEQ ID No. 595, their analogues and derivatives.

48. (New) Pharmaceutical compositions of the Evasins, their analogues and derivatives according to claim 32, characterized by the increase of the biodisponibility of the cited Evasins when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or mixed.

49. (New) Pharmaceutical compositions of the Evasins, their analogues and derivatives according to claim 32 characterized by the increase of the duration and/or efficacy of the Evasins effect, their analogues and derivatives when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or mixed.

50. (New) Oral pharmaceutical compositions of the Evasins, their analogues and derivatives, according claim 32 to be use in the treatment of hypertensive emergency characterized by the used of the mixture with excipients pharmaceutically acceptable including water, saline solution, buffer solutions, Ringer solution, dextrose solution, Hank solution, Biocompatible saline solutions, containing or not polyethylene glycol.

51. (New) Oral pharmaceutical compositions of the Evasins, its analogues and derivatives according to claim 32 characterized by the increase of the biodisponibility of the cited Evasins when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or mixed.

52. (New) Pharmaceutical compositions oral of the Evasins, their analogues and derivatives according to claim 32 characterized by the increase of the duration and/or efficacy of the Evasins effect, their analogues and derivatives when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or mixed.

53. (New) Compositions and formulations for intramuscular, subcutaneous, topic, inhalatory (pulmonary, intranasal, intramouth) administration or as device that can be implanted or injected, of the Evasins, their analogues and derivatives according to claim 32 characterized by the increase of the biodisponibility of the cited Evasins, their analogues and derivatives when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or in mixture.

54. (New) Compositions and formulations for intramuscular, subcutaneous, topic, inhalatory (pulmonary, intranasal, intramouth) administration or as device that can be implated or injected, of the Evasins, their analogues and derivatives according to claim 32 characterized by the increase of the biodisponibility of the cited Evasins, their analogues and derivatives when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or in mixture or mixed or associated at least with another agent pharmacologically active microencapsulated or not in controlled-release systems such as liposome and the biodegradable polymers and/or mixtures.

55. (New) Compositions and formulations for intramuscular, subcutaneous, topic, inhalatory (pulmonary, intranasal, intramouth) administration and as device that can be implanted or injected, of the Evasins, their analogues or derivatives according to claim 32 characterized by the increase of the duration and/or efficacy of the cited Evasins, their analogues or derivatives when

included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or mixed .

56. (New) Compositions and formulations for intramuscular, subcutaneous, topical, inhalatory (pulmonary, intranasal, intramouth) administration or as device that can be implanted or injected, of the Evasins, their analogues and derivatives used in the study and treatment of the arterial hypertension and others cardiovascular diseases and their complications according to claim 32, characterized by the use of the Evasins their analogues and derivatives when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or in mixture associated, at least, with an additional pharmacologically active agent microencapsulated or not in controlled-release systems such as liposomes and biodegradable polymers and/or mixtures thereof.

57. (New) Compositions and formulations for intramuscular, subcutaneous, topical, inhalatory (pulmonary, intranasal, intramouth) administration or as device that can be implanted or injected, of the Evasins, their analogues and derivatives used in the study and treatment of the acute myocardial infarction, left ventricular hypertrophy, diabetic vasculopathy, peripheral ischemia, angina, progressive heart failure after a myocardial infarction, atherosclerosis, tumors, diabetes melitus, sperm motility, blockade of spermatogenesis, nephropathies, sexual dysfunction, gastrointestinal and gynecologic disorders, angiogenesis, hair loss, blood diseases, angioplasty (restenosis after-angioplasty, endoluminal prosthesis) in warm-blood animals according to claim 32

characterized by the use of the Evasins their analogues and derivatives when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or in mixture associated, at least, with an additional pharmacologically active agent microencapsulated or not in controlled-release systems such as liposomes and biodegradable polymers and/or mixtures, thereof.

58. (New) Pharmaceutical compositions for intramuscular, subcutaneous, topic, inhalatory (pulmonary, intranasal, intramouth) administration or as device that can be implanted or injected, of the Evasins, their analogues and derivatives according to claim 32 characterized by the increase of the biodisponibility of the cited Evasins, their analogues and derivatives when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or mixed or associated at least with an additional pharmacologically active agent microencapsulated or not in controlled-release systems such as liposome and the biodegradable polymers and/or mixtures.

59. (New) Pharmaceutical compositions and formulations for intramuscular, subcutaneous, topic, inhalatory (pulmonary, intranasal, intramouth) administration or as device that can be implanted or injected, of the Evasins, their analogues and derivatives according to claim 32, characterized by the increase of the duration and/or efficacy of the Evasins effect, their analogues and derivatives when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or mixed

60. (New) Pharmaceutical compositions, intramuscular, intravenous, subcutaneous, topic, inhalation (pulmonary, intranasal, intramouth) or as device that can be implanted or injected, of the Evasins, their analogues structural and conformational according to claim 32 characterized by the increase of the duration and/or efficacy of the Evasins, their analogues and derivatives effect when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or mixed, at least, with an additional pharmacologically active agent and/or microencapsulated or not in controlled-release systems such as liposomes and biodegradable polymers and/or mixtures, thereof.

61. (New) Pharmaceutical compositions for intramuscular, intravenous, subcutaneous, topic, inhalation (pulmonary, intranasal, intramouth) administration or as device that can be implanted or injected, of the Evasins, their analogues and derivatives used in the study and treatment of arterial hypertension and others cardiovascular and their complications according to claim 32, characterized by the use of the Evasins their analogues and derivatives when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or in mixture associated at least with an additional pharmacologically active agent microencapsulated or not in controlled-release systems such as the liposomes and biodegradable polymers and/or mixtures, thereof.

62. (New) Pharmaceutical compositions for intramuscular, intravenous, subcutaneous, topical, inhalation (pulmonary, intranasal, intramouth) or as device that can be implanted or injected, of the Evasins, their analogues and derivatives used in the study and treatment of the acute myocardial infarction, stroke, left ventricular hypertrophy, diabetic vasculopathy, peripheral ischemia, angina, progressive heart failure after a myocardial infarction, atherosclerosis, tumors, diabetes melitus, sperm motility, blockade spermatogenesis, nephropathies, sexual impotence, gastrointestinal and gynecologic disorders, angiogenesis, hair loss, blood diseases, angioplasty (restenosis after-angioplasty, endoluminal protese) in warm-blood animals according to claim 32 characterized by the use of the Evasins their analogues and derivatives when included in cyclodextrins or their derivatives, or associated or included in carriers and/or excipients pharmaceutically acceptable, alone or in mixture associated, at least, with an additional pharmacologically active agent microencapsulated or not in controlled-release systems such as the liposomes and biodegradable polymers and/or mixtures thereof.